PARADISE-MI Obscured As Post Hoc Analysis Finds Flaws

A post-hoc analysis of the PARADISE-MI trial suggests relevant benefits are being missed in current trial design.

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Brazil ,Johann Bauersachs ,Otavio Berwanger ,Bristol Myers Squibb ,Amgen ,American College Of Cardiology ,Boehringer Ingelheim ,Novartis ,Pfizer ,Astrazeneca ,European Society Of Cardiology ,Hannover Germany Medical School ,Academic Research Organization ,Hospital Israelita Albert Einstein ,European Society ,New England Journal ,Adjudicated Outcomes Differ ,American College ,Heart Failure ,Myocardial Infarction ,Angiotensin Converting Enzyme Inhibitor ,Ace Inhibitor ,Generics ,Generic Drug ,Eneric Medication ,Pulmonary Edema ,Hospitals ,Inpatient Care ,Left Ventricular Dysfunction ,